$SBRA
Sabra Health Care REIT, Inc. Stock $sbra

$sbra Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000149229823000021 Filed on August 07, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	$161.6M	$161.2M
YoY Change	14.82%	3.34%
Cost Of Revenue	$44.52M	$43.96M
YoY Change	21.3%	29.21%
Gross Profit	$117.1M	$117.2M
YoY Change	12.54%	-3.88%
Gross Profit Margin	72.45%	72.72%
Selling, General & Admin	$11.09M	$9.961M
YoY Change	17.21%	18.88%
% of Gross Profit	9.47%	8.5%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$43.24M	$44.14M
YoY Change	-8.82%	-2.28%
% of Gross Profit	36.93%	37.66%
Operating Expenses	$58.63M	$58.87M
YoY Change	-5.44%	0.81%
Operating Profit	$58.47M	$58.33M
YoY Change	39.04%	-8.19%
Interest Expense	-$28.80M	-$28.98M
YoY Change	-8.44%	3.29%
% of Operating Profit	-49.26%	-49.69%
Other Income/Expense, Net	-$44.32M	-$7.833M
YoY Change	-5825.58%	17.54%
Pretax Income	-$14.00M	$22.17M
YoY Change	-68.96%	13.16%
Income Tax	$455.0K	$326.0K
% Of Pretax Income		1.47%
Net Earnings	-$15.10M	$21.19M
YoY Change	-69.84%	26.08%
Net Earnings / Revenue	-9.34%	13.15%
Basic Earnings Per Share	-$0.07	$0.09
Diluted Earnings Per Share	-$0.07	$0.09
COMMON SHARES
Basic Shares Outstanding	231.2M shares	231.2M shares
Diluted Shares Outstanding	231.2M shares	232.2M shares

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$33.26M	$27.23M
YoY Change	26.5%	-59.44%
Cash & Equivalents	$33.26M	$27.23M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$185.5M	$173.9M
YoY Change	6.02%	-29.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.603B	$4.752B
YoY Change	-8.29%	-5.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$135.8M	$140.4M
YoY Change	-34.61%	-36.16%
Other Assets	$5.602M	$5.146M
YoY Change	15.29%	17.81%
Total Long-Term Assets	$5.195B	$5.350B
YoY Change	-8.38%	-6.37%
TOTAL ASSETS
Total Short-Term Assets	$185.5M	$173.9M
Total Long-Term Assets	$5.195B	$5.350B
Total Assets	$5.381B	$5.524B
YoY Change	-7.94%	-7.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$106.9M	$105.5M
YoY Change	-13.21%	4.34%
Accrued Expenses	$21.10M	$16.40M
YoY Change	-4.09%	-1.2%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$128.0M	$121.9M
YoY Change	-11.83%	3.55%
LONG-TERM LIABILITIES
Long-Term Debt	$2.349B	$2.420B
YoY Change	-3.98%	-2.43%
Other Long-Term Liabilities	$34.19M	$38.69M
YoY Change	-22.33%	-15.54%
Total Long-Term Liabilities	$2.384B	$2.459B
YoY Change	-4.31%	-2.66%
TOTAL LIABILITIES
Total Short-Term Liabilities	$128.0M	$121.9M
Total Long-Term Liabilities	$2.384B	$2.459B
Total Liabilities	$2.512B	$2.581B
YoY Change	-4.72%	-2.39%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$2.312M	$2.312M
YoY Change	0.09%	0.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.869B	$2.944B
YoY Change
Total Liabilities & Shareholders Equity	$5.381B	$5.524B
YoY Change	-7.94%	-7.33%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$15.10M	$21.19M
YoY Change	-69.84%	26.08%
Depreciation, Depletion And Amortization	$43.24M	$44.14M
YoY Change	-8.82%	-2.28%
Cash From Operating Activities	$83.22M	$70.33M
YoY Change	-23.28%	-8.15%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$59.93M	-$8.193M
YoY Change	833.01%	-90.98%
Cash From Investing Activities	$59.93M	-$8.193M
YoY Change	-205.16%	-90.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-136.4M	-68.47M
YoY Change	48.87%	-222.38%
NET CHANGE
Cash From Operating Activities	83.22M	70.33M
Cash From Investing Activities	59.93M	-8.193M
Cash From Financing Activities	-136.4M	-68.47M
Net Change In Cash	6.750M	-6.337M
YoY Change	-116.81%	-115.21%
FREE CASH FLOW
Cash From Operating Activities	$83.22M	$70.33M
Capital Expenditures	$0.00	$0.00
Free Cash Flow	$83.22M	$70.33M
YoY Change	-51.58%	-8.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent http://fasb.org/us-gaap/2023#LineOfCredit http://fasb.org/us-gaap/2023#LoansPayableToBank
CY2022Q4	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent http://fasb.org/us-gaap/2023#LineOfCredit http://fasb.org/us-gaap/2023#LoansPayableToBank
CY2023Q2	us-gaap	Derivative Asset Statement Of Financial Position Extensible Enumeration DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration	http://www.sabrahealth.com/20230630#AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet
CY2023Q2	us-gaap	Derivative Asset Statement Of Financial Position Extensible Enumeration DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration	http://www.sabrahealth.com/20230630#AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	336770000	usd
	us-gaap	Repayments Of Medium Term Notes RepaymentsOfMediumTermNotes	0	usd
	us-gaap	Repayments Of Medium Term Notes RepaymentsOfMediumTermNotes	40000000	usd
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	983000	usd
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	16547000	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	18128000	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	6000	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	17900000	usd
	sbra	Proceeds Payments From Issuance Of Stock Net Of Taxes Paid On Behalf Of Employees ProceedsPaymentsFromIssuanceOfStockNetOfTaxesPaidOnBehalfOfEmployees	-2153000	usd
	sbra	Proceeds Payments From Issuance Of Stock Net Of Taxes Paid On Behalf Of Employees ProceedsPaymentsFromIssuanceOfStockNetOfTaxesPaidOnBehalfOfEmployees	-3803000	usd
	us-gaap	Payments Of Dividends PaymentsOfDividends	138711000	usd
	us-gaap	Payments Of Dividends PaymentsOfDividends	138565000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-264544000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-56568000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-20944000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-44984000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-608000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	619000	usd
	us-gaap	Interest Paid Net InterestPaidNet	52591000	usd
	us-gaap	Interest Paid Net InterestPaidNet	49968000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	4644000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	5623000	usd
CY2023Q2	sbra	Real Estate Investments Joint Ventures Number RealEstateInvestmentsJointVenturesNumber	0	investment
CY2023Q2	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	375316000	usd
CY2023Q2	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	359991000	usd
	us-gaap	Use Of Estimates UseOfEstimates	The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y
CY2023Q2	us-gaap	Security Deposit Liability SecurityDepositLiability	16800000	usd
CY2022Q4	us-gaap	Security Deposit Liability SecurityDepositLiability	13100000	usd
CY2023Q2	sbra	Letters Of Credit Deposits LettersOfCreditDeposits	59000000	usd
CY2022Q4	sbra	Letters Of Credit Deposits LettersOfCreditDeposits	57000000	usd
CY2023Q2	sbra	Property Taxes Insurance And Tenant Improvement Deposit Liability PropertyTaxesInsuranceAndTenantImprovementDepositLiability	14000000	usd
CY2022Q4	sbra	Property Taxes Insurance And Tenant Improvement Deposit Liability PropertyTaxesInsuranceAndTenantImprovementDepositLiability	13300000	usd
CY2023Q2	us-gaap	Variable Lease Income VariableLeaseIncome	3800000	usd
	us-gaap	Variable Lease Income VariableLeaseIncome	7600000	usd
CY2022Q2	us-gaap	Variable Lease Income VariableLeaseIncome	4400000	usd
	us-gaap	Variable Lease Income VariableLeaseIncome	9400000	usd
CY2023Q2	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	188220000	usd
CY2023Q2	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	379861000	usd
CY2023Q2	sbra	Lessor Operating Lease Payment To Be Received After Year Four LessorOperatingLeasePaymentToBeReceivedAfterYearFour	1534405000	usd
CY2023Q2	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	3174563000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	56000000	usd
CY2023Q2	us-gaap	Equity Method Investments EquityMethodInvestments	140402000	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	134962000	usd
	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	7100000	usd
	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	11700000	usd
	sbra	Disposal Group Including Discontinued Operations Number Of Properties DisposalGroupIncludingDiscontinuedOperationsNumberOfProperties	12	facility
	sbra	Disposal Group Including Discontinued Operations Number Of Properties DisposalGroupIncludingDiscontinuedOperationsNumberOfProperties	8	facility
CY2023Q2	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	176900000	usd
CY2022Q2	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	40000000.0	usd
CY2023Q2	sbra	Disposal Group Including Discontinued Operation Assets And Liabilities Net DisposalGroupIncludingDiscontinuedOperationAssetsAndLiabilitiesNet	206300000	usd
CY2022Q2	sbra	Disposal Group Including Discontinued Operation Assets And Liabilities Net DisposalGroupIncludingDiscontinuedOperationAssetsAndLiabilitiesNet	44500000	usd
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-29400000	usd
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-4500000	usd
	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-37400000	usd
	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-2400000	usd
	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	7100000	usd
CY2023Q2	sbra	Financing Receivable Number Of Loans FinancingReceivableNumberOfLoans	13	loan
CY2023Q2	sbra	Financing Receivable Principal Amount FinancingReceivablePrincipalAmount	371538000	usd
CY2023Q2	us-gaap	Notes Receivable Gross NotesReceivableGross	368116000	usd
CY2022Q4	us-gaap	Notes Receivable Gross NotesReceivableGross	366936000	usd
CY2023Q2	sbra	Financing Receivable Fixed Interest Rate FinancingReceivableFixedInterestRate	0.076
CY2023Q2	sbra	Financing Receivable Effective Interest Rate FinancingReceivableEffectiveInterestRate	0.076
CY2023Q2	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	6832000	usd
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	6611000	usd
CY2023Q2	sbra	Financing Receivable Principal Amount FinancingReceivablePrincipalAmount	371538000	usd
CY2023Q2	us-gaap	Notes Receivable Net NotesReceivableNet	361284000	usd
CY2022Q4	us-gaap	Notes Receivable Net NotesReceivableNet	360325000	usd
CY2023Q2	sbra	Preferred Equity Investments Number PreferredEquityInvestmentsNumber	5	preferredequityinvestment
CY2023Q2	sbra	Preferred Equity Investment Face Value PreferredEquityInvestmentFaceValue	55581000	usd
CY2023Q2	sbra	Preferred Equity Investment Carrying Amount PreferredEquityInvestmentCarryingAmount	55735000	usd
CY2022Q4	sbra	Preferred Equity Investment Carrying Amount PreferredEquityInvestmentCarryingAmount	51071000	usd
CY2023Q2	sbra	Preferred Equity Investment Weighted Average Contractual Rate PreferredEquityInvestmentWeightedAverageContractualRate	0.109
CY2023Q2	sbra	Preferred Equity Investment Weighted Average Effective Rate PreferredEquityInvestmentWeightedAverageEffectiveRate	0.109
CY2023Q2	sbra	Number Of Investments NumberOfInvestments	18	investment
CY2023Q2	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	427119000	usd
CY2023Q2	sbra	Financing Receivable And Other Investments Net FinancingReceivableAndOtherInvestmentsNet	417019000	usd
CY2022Q4	sbra	Financing Receivable And Other Investments Net FinancingReceivableAndOtherInvestmentsNet	411396000	usd
CY2023Q2	sbra	Investments Weighted Average Contractual Rate InvestmentsWeightedAverageContractualRate	0.081
CY2023Q2	sbra	Investments Weighted Average Effective Rate InvestmentsWeightedAverageEffectiveRate	0.080
	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	221000	usd
	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	268000	usd
CY2022Q2	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	6612000	usd
CY2023Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	28300000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	56900000	usd
CY2022Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	25500000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	50500000	usd
CY2023Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3100000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	6100000	usd
CY2022Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2800000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	5500000	usd
CY2023Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	16400000	usd
CY2022Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	18200000	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	996000	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	2034000	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2089000	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	502147000	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	202723000	usd
CY2023Q2	sbra	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	1732888000	usd
CY2023Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2442877000	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	3895000	usd
CY2023Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	18946000	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	2420036000	usd
CY2023Q2	sbra	Other Comprehensive Income Loss Cash Flow And Net Investment Hedge Gain Loss Before Reclassification And Tax OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax	10746000	usd
CY2022Q2	sbra	Other Comprehensive Income Loss Cash Flow And Net Investment Hedge Gain Loss Before Reclassification And Tax OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax	10618000	usd
	sbra	Other Comprehensive Income Loss Cash Flow And Net Investment Hedge Gain Loss Before Reclassification And Tax OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax	11110000	usd
	sbra	Other Comprehensive Income Loss Cash Flow And Net Investment Hedge Gain Loss Before Reclassification And Tax OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax	17767000	usd
CY2023Q2	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	31124000	usd
CY2023Q2	us-gaap	Derivative Asset Fair Value Gross Liability DerivativeAssetFairValueGrossLiability	0	usd
CY2023Q2	us-gaap	Derivative Assets DerivativeAssets	31124000	usd
CY2023Q2	us-gaap	Derivative Collateral Obligation To Return Securities DerivativeCollateralObligationToReturnSecurities	0	usd
CY2023Q2	us-gaap	Derivative Collateral Obligation To Return Cash DerivativeCollateralObligationToReturnCash	0	usd
CY2023Q2	us-gaap	Derivative Fair Value Of Derivative Asset Amount Offset Against Collateral DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral	31124000	usd
CY2023Q2	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	0	usd
CY2023Q2	us-gaap	Derivative Liability Fair Value Gross Asset DerivativeLiabilityFairValueGrossAsset	0	usd
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	0	usd
CY2023Q2	us-gaap	Derivative Collateral Right To Reclaim Securities DerivativeCollateralRightToReclaimSecurities	0	usd
CY2023Q2	us-gaap	Derivative Collateral Right To Reclaim Cash DerivativeCollateralRightToReclaimCash	0	usd
CY2023Q2	us-gaap	Derivative Fair Value Of Derivative Liability Amount Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral	0	usd
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	21477000	usd
CY2022Q4	us-gaap	Derivative Asset Fair Value Gross Liability DerivativeAssetFairValueGrossLiability	0	usd
CY2022Q4	us-gaap	Derivative Assets DerivativeAssets	21477000	usd
CY2022Q4	us-gaap	Derivative Collateral Obligation To Return Securities DerivativeCollateralObligationToReturnSecurities	0	usd
CY2022Q4	us-gaap	Derivative Collateral Obligation To Return Cash DerivativeCollateralObligationToReturnCash	0	usd
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Asset Amount Offset Against Collateral DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral	21477000	usd
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	0	usd
CY2022Q4	us-gaap	Derivative Liability Fair Value Gross Asset DerivativeLiabilityFairValueGrossAsset	0	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	0	usd
CY2022Q4	us-gaap	Derivative Collateral Right To Reclaim Securities DerivativeCollateralRightToReclaimSecurities	0	usd
CY2022Q4	us-gaap	Derivative Collateral Right To Reclaim Cash DerivativeCollateralRightToReclaimCash	0	usd
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Liability Amount Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral	0	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
CY2023Q2	sbra	Financing Receivable Principal Amount FinancingReceivablePrincipalAmount	371538000	usd
CY2022Q4	sbra	Financing Receivable Principal Amount FinancingReceivablePrincipalAmount	370364000	usd
CY2023Q2	sbra	Preferred Equity Investment Face Value PreferredEquityInvestmentFaceValue	55581000	usd
CY2022Q4	sbra	Preferred Equity Investment Face Value PreferredEquityInvestmentFaceValue	50902000	usd
CY2023Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.30
CY2023Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.30
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1400000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3300000	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	21188000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	16805000	usd
	us-gaap	Net Income Loss NetIncomeLoss	11701000	usd
	us-gaap	Net Income Loss NetIncomeLoss	57407000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	231204531	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	230967163	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	231184355	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	230913462	shares
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1040057	shares
CY2022Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	714373	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1030088	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	728496	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	232244588	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	231681536	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	232214443	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	231641958	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.09
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.25
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
CY2023Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0001492298-23-000021-index-headers.html	Edgar Link	pending
0001492298-23-000021-index.html	Edgar Link	pending
0001492298-23-000021.txt	Edgar Link	pending
0001492298-23-000021-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sbra-20230630.htm	Edgar Link	pending
sbra-20230630.xsd	Edgar Link	pending
sbraex3112023q2.htm	Edgar Link	pending
sbraex3122023q2.htm	Edgar Link	pending
sbraex3212023q2.htm	Edgar Link	pending
sbraex3222023q2.htm	Edgar Link	pending
Show.js	Edgar Link	pending
sbra-20230630_def.xml	Edgar Link	unprocessable
sbra-20230630_lab.xml	Edgar Link	unprocessable
sbra-20230630_pre.xml	Edgar Link	unprocessable
sbra-20230630_htm.xml	Edgar Link	completed
sbra-20230630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SBRA
Sabra Health Care REIT, Inc. Stock $sbra

2023 Q3 Form 10-Q Financial Statement

#000149229823000021 Filed on August 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SBRA Sabra Health Care REIT, Inc. Stock $sbra

2023 Q3 Form 10-Q Financial Statement

#000149229823000021 Filed on August 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SBRA
Sabra Health Care REIT, Inc. Stock $sbra